Dr. Fidias is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 Alumni Dr
Exeter, NH 03833Phone+1 603-580-7054Fax+1 603-580-6747
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1996
- University at BuffaloResidency, Internal Medicine, 1990 - 1993
- University of AthensClass of 1990
Certifications & Licensure
- MA State Medical License 1993 - 2025
- NH State Medical License 2013 - 2025
- AZ State Medical License 2014 - 2017
- TX State Medical License 1997 - 1999
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer Start of enrollment: 2006 Nov 01
Publications & Presentations
PubMed
- CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer.John Sharp, Daniel Jones, Julia Rotow, Panos Fidias, Erin Bertino
Journal of the National Comprehensive Cancer Network. 2024-04-05 - Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.John A Sharp, Daniel Jones, Julia K Rotow, Panos M Fidias, Erin Bertino
Journal of the National Comprehensive Cancer Network. 2024-03-13 - Phase II Study of Cabozantinib in Patients With Bone Metastasis.Edwin Choy, Gregory M Cote, M Dror Michaelson, Lori Wirth, Justin F Gainor
The Oncologist. 2022-07-05
Press Mentions
- Minimally Invasive Surgery Lessens Pain of Esophageal CancerAugust 24th, 2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: